Active substance venetoclax
Holder Abbvie
Status Running
Indication in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients who are ineligible for intensive chemotherapy and who have no other suitable treatment option and are not eligible to participate in a clinical study for their serious condition.
Public documents Approbation
  Information for the patient
  Informed consent
Last update 16/02/2021


Last updated on 03/05/2021